Dear Friend,
As the year draws to a close, the cystic fibrosis community has much to celebrate. Thanks to your unwavering commitment and dedication, in 2022, we continued to make tremendous progress in advancing our mission. Here are just a few of the many accomplishments we achieved together:
|
|
|
|
- For the first time, the median predicted life expectancy for a child born with CF today has reached 53 years, up 15 years from just a decade ago.
- We now have a drug development pipeline with more programs than ever before. The CF Foundation’s collaborations with leading biotech and venture capital firms have resulted in 35 major industry research programs focused on genetic science, allowing us to boldly advance our Path to a Cure initiative.
-
Several clinical trials for CF genetic therapies are underway or will begin in the coming year, including three promising mRNA therapies.
-
We continue to study the effects of modulators, as well as pursue the next generation of modulator therapies and expand existing modulators to younger children.
- CF care teams offered highly specialized care through our extraordinary network of more than 130 CF care centers nationwide, which the Foundation helps fund.
-
We reaffirmed our commitment to equity, racial justice, diversity, and inclusion, partnering with members of our community to better understand the health disparities that people of color with CF face. We are taking concrete steps to address these disparities, including establishing a newborn screening initiative to improve equity in diagnosis and ensuring that we have more diverse representation in CF clinical trials.
- To further fuel our mission, we officially launched the Milestones III: Driven by a Dream campaign this summer and have already raised $110 million, which is more than halfway toward our goal.
-
For the first time in nearly three years, we gathered again at hundreds of in-person events nationwide and held inspiring virtual events led by people with CF, such as BreatheCon and ROSE UP.
-
Additionally, in July, we welcomed Steven Rowe, MD – a leader in the international CF research community – as our new Chief Scientific Officer.
-
We also welcomed KC White as the first adult with CF to lead the Board of Trustees. KC will build on the legacy of our Immediate Past Chair, Cam McLoud, whose dedicated service helped transform CF over the past two decades.
|
As we move into 2023, the future looks bright. Together, we will continue to drive our mission forward so that every person with cystic fibrosis can live a long, healthy life. And with you by our side, I am confident that we will realize our shared dream – a cure for CF.
Best wishes for a safe and happy holiday season,
Michael P. Boyle, MD
President and CEO
|
|
|
MAKE A YEAR-END GIFT TODAY
|
|
|
|
4550 Montgomery Avenue, Suite 1100N | Bethesda, MD 20814 US
|
|
Got this as a forward? Sign up to receive our future emails.
Opt out of this mailing list | Opt out of all CFF emails
|
|
|
This email was sent to [email protected].
To continue receiving our emails, add us to your address book.
|
|
|
|
